Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from ANGLE plc ( (GB:AGL) ) is now available.
ANGLE plc announced that it will release its preliminary results for the year ended 31 December 2024 on 28 May 2025. The company will host an analyst meeting at FTI Consulting in London, with a live webcast available for registered participants. This announcement highlights ANGLE’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, offering innovative circulating tumour cell (CTC) diagnostic solutions. Their primary products include the FDA-cleared Parsortix PC1 System, which facilitates comprehensive downstream analysis of blood samples for research, drug development, and clinical oncology. The company focuses on clinical services and diagnostic products, with services provided through GCLP-compliant laboratories.
Average Trading Volume: 1,031,813
Technical Sentiment Signal: Sell
Current Market Cap: £25.8M
For a thorough assessment of AGL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue